Heart Failure With Preserved Ejection Fraction

Yogesh N V Reddy, Barry A Borlaug

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Heart failure (HF) is one of the largest drivers of morbidity and health care expenditure in the world and continues to increase in prevalence at an alarming rate. Most of this increasing burden is related to the rapidly expanding population of HF with preserved ejection fraction (HFpEF), largely driven by the increasing rates of obesity, hypertension, and metabolic syndrome in western countries. In the last 3 decades, there have been tremendous advances in treating patients with HF with reduced ejection fraction (HFrEF), with essentially no change in outcomes for HFpEF. The lack of efficacy for established HFrEF therapies in HFpEF underscores the fundamental differences between both these phenotypically distinct forms of HF. In this review, we will summarize the current understanding of the pathophysiology of HFpEF, discuss diagnostic and therapeutic strategies, and provide future avenues to direct clinical investigation.

Original languageEnglish (US)
JournalCurrent Problems in Cardiology
DOIs
StateAccepted/In press - 2016

Fingerprint

Heart Failure
Health Expenditures
Obesity
Hypertension
Morbidity
Delivery of Health Care
Therapeutics
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Heart Failure With Preserved Ejection Fraction. / Reddy, Yogesh N V; Borlaug, Barry A.

In: Current Problems in Cardiology, 2016.

Research output: Contribution to journalArticle

@article{d8869546ffcb4679a0248cba26078c29,
title = "Heart Failure With Preserved Ejection Fraction",
abstract = "Heart failure (HF) is one of the largest drivers of morbidity and health care expenditure in the world and continues to increase in prevalence at an alarming rate. Most of this increasing burden is related to the rapidly expanding population of HF with preserved ejection fraction (HFpEF), largely driven by the increasing rates of obesity, hypertension, and metabolic syndrome in western countries. In the last 3 decades, there have been tremendous advances in treating patients with HF with reduced ejection fraction (HFrEF), with essentially no change in outcomes for HFpEF. The lack of efficacy for established HFrEF therapies in HFpEF underscores the fundamental differences between both these phenotypically distinct forms of HF. In this review, we will summarize the current understanding of the pathophysiology of HFpEF, discuss diagnostic and therapeutic strategies, and provide future avenues to direct clinical investigation.",
author = "Reddy, {Yogesh N V} and Borlaug, {Barry A}",
year = "2016",
doi = "10.1016/j.cpcardiol.2015.12.002",
language = "English (US)",
journal = "Current Problems in Cardiology",
issn = "0146-2806",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Heart Failure With Preserved Ejection Fraction

AU - Reddy, Yogesh N V

AU - Borlaug, Barry A

PY - 2016

Y1 - 2016

N2 - Heart failure (HF) is one of the largest drivers of morbidity and health care expenditure in the world and continues to increase in prevalence at an alarming rate. Most of this increasing burden is related to the rapidly expanding population of HF with preserved ejection fraction (HFpEF), largely driven by the increasing rates of obesity, hypertension, and metabolic syndrome in western countries. In the last 3 decades, there have been tremendous advances in treating patients with HF with reduced ejection fraction (HFrEF), with essentially no change in outcomes for HFpEF. The lack of efficacy for established HFrEF therapies in HFpEF underscores the fundamental differences between both these phenotypically distinct forms of HF. In this review, we will summarize the current understanding of the pathophysiology of HFpEF, discuss diagnostic and therapeutic strategies, and provide future avenues to direct clinical investigation.

AB - Heart failure (HF) is one of the largest drivers of morbidity and health care expenditure in the world and continues to increase in prevalence at an alarming rate. Most of this increasing burden is related to the rapidly expanding population of HF with preserved ejection fraction (HFpEF), largely driven by the increasing rates of obesity, hypertension, and metabolic syndrome in western countries. In the last 3 decades, there have been tremendous advances in treating patients with HF with reduced ejection fraction (HFrEF), with essentially no change in outcomes for HFpEF. The lack of efficacy for established HFrEF therapies in HFpEF underscores the fundamental differences between both these phenotypically distinct forms of HF. In this review, we will summarize the current understanding of the pathophysiology of HFpEF, discuss diagnostic and therapeutic strategies, and provide future avenues to direct clinical investigation.

UR - http://www.scopus.com/inward/record.url?scp=84964318210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964318210&partnerID=8YFLogxK

U2 - 10.1016/j.cpcardiol.2015.12.002

DO - 10.1016/j.cpcardiol.2015.12.002

M3 - Article

JO - Current Problems in Cardiology

JF - Current Problems in Cardiology

SN - 0146-2806

ER -